The addition of enzalutamide to androgen deprivation therapy extended metastasis-free survival among men with nonmetastatic, hormone-sensitive prostate cancer with high-risk biochemical recurrence, according to study results.The findings of the randomized, phase 3 EMBARK study, presented during American Urological Association Annual Meeting, also showed a statistically significant and clinically